Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Issued: March 1988 Prosecuted by: Ben D. Tobor of Houston’s Tobor Goldstein and Healey Litigated by: Gregory Diskant and William Cavanaugh, Jr., of New York’s Patterson, Belknap, Webb & Tyler There’s a bit of irony in Johnson & Johnson’s handling of the market in cardiac stents — those little wire-cage devices that keep arteries propped open after angioplasties. J&J’s domination of the market went into cardiac arrest almost immediately after two companies introduced competing stent products. J&J’s 90 percent market share dwindled to 10 percent in the first 45 days of competition. For resuscitation, J&J turned to their lawyers. In 1997, lead counsel Gregory Diskant and William Cavanaugh, Jr., of New York’s Patterson, Belknap, Webb & Tyler took on stent competitors Medtronics AVE Inc., Boston Scientific Corp., and Guidant, Inc. The Boston Scientific and Medtronics cases went to trial back-to-back last year in Delaware federal court. Diskant compares the litigations to “consecutive marathons.” We call them screaming victories. The Boston Scientific jury came back on November 21, and awarded J&J a whopping $324.4 million in damages. Just three weeks later, the Medtronics jury awarded J&J $271.1 million. Defense attorneys in both cases have said they will appeal. If J&J’s verdicts are upheld, Boston Scientific and Medtronics will need to seek licensing deals with J&J — or get out of the stent business. (Guidant has settled for an undisclosed amount.)Since the verdicts, J&J’s market share has been steadily climbing. Analysts say that J&J has rebounded to about 20 percent of the volatile $1.5 billion market. And observers expect J& J to regain its status as a major market player.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]

Reprints & Licensing
Mentioned in a Law.com story?

License our industry-leading legal content to extend your thought leadership and build your brand.


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.